Anaptysbio (ANAB) EBT (2016 - 2026)
Anaptysbio posted quarterly EBT of -$52.8 million for Q1 2026, down 34.51% year-on-year from -$80.7 million in Q1 2025, and down 184.2% on a QoQ basis from $62.8 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of EBT data on file, last reported at -$52.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 34.51% year-over-year to -$52.8 million; the trailing twelve-month figure through Mar 2026 stood at -$13.6 million (up 90.36% YoY), and the FY2024 full-year result was -$145.4 million, down 337962.79% from the prior year.
- EBT for Q1 2026 stood at -$52.8 million, down from $62.8 million in the prior quarter.
- Across five years, EBT topped out at $121.4 million in Q4 2023 and bottomed at -$52.8 million in Q1 2026.
- The 5-year median for EBT is -$32.9 million (2024), against an average of -$17.7 million.
- The widest annual swing landed in 2022, when EBT tumbled 6121.91%; it then surged 648.32% in 2023.
- A 5-year view of EBT shows it stood at -$22.1 million in 2022, then soared by 648.32% to $121.4 million in 2023, then sank by 118.07% to -$21.9 million in 2024, then jumped by 386.21% to $62.8 million in 2025, then plunged by 184.2% to -$52.8 million in 2026.
- The last three EBT figures came in at -$52.8 million (Q1 2026), $62.8 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | -52.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.84 Mn |
| Dec 31, 2025 | 62.76 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.59 Mn |
| Mar 31, 2025 | -39.29 Mn |
| Dec 31, 2024 | -21.93 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.65 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | 121.37 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -39.92 Mn |
| Dec 31, 2022 | -22.13 Mn |
| Sep 30, 2022 | -27.37 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -31.41 Mn |
| Dec 31, 2021 | -31.09 Mn |
| Sep 30, 2021 | -6.70 Mn |
| Jun 30, 2021 | -429,000.00 |
| Mar 31, 2021 | -18.17 Mn |
| Dec 31, 2020 | 33.65 Mn |
| Sep 30, 2020 | -23.77 Mn |
| Jun 30, 2020 | -21.55 Mn |
| Mar 31, 2020 | -8.26 Mn |
| Dec 31, 2019 | -20.29 Mn |
| Sep 30, 2019 | -31.08 Mn |
| Jun 30, 2019 | -24.02 Mn |
| Mar 31, 2019 | -22.10 Mn |
| Dec 31, 2018 | -17.19 Mn |
| Sep 30, 2018 | -15.96 Mn |
| Jun 30, 2018 | -13.62 Mn |
| Mar 31, 2018 | -15.09 Mn |
| Dec 31, 2017 | -6.75 Mn |
| Sep 30, 2017 | -9.18 Mn |
| Jun 30, 2017 | -2.71 Mn |
| Mar 31, 2017 | -10.29 Mn |
| Dec 31, 2016 | -3.29 Mn |
| Sep 30, 2016 | -1.19 Mn |
| Jun 30, 2016 | 2.25 Mn |
| Mar 31, 2016 | -1.25 Mn |